Prognostic Value of Albumin-To-Fibrinogen Ratio and Fibrinogen and Albumin Score in Lung Cancer Patients: A Meta-Analysis

IF 1.6 4区医学 Q3 SURGERY

ANZ Journal of Surgery Pub Date : 2025-07-11 DOI:10.1111/ans.70253

Zongyuan Li, Yueli Shu, Wenying Xu, Jian Zhang

{"title":"Prognostic Value of Albumin-To-Fibrinogen Ratio and Fibrinogen and Albumin Score in Lung Cancer Patients: A Meta-Analysis","authors":"Zongyuan Li, Yueli Shu, Wenying Xu, Jian Zhang","doi":"10.1111/ans.70253","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>We aim to comprehensively assess the prognostic performance of AFR and FA scores in patients with lung cancer (LC).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We conducted a comprehensive search of PubMed, Web of Science, and CNKI databases to identify relevant studies. The primary endpoints assessed were overall survival (OS) and progression-free survival (PFS). Integrated hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated through pooling analysis.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 3145 participants from 10 studies were included in the analysis. In LC patients, the pooled results showed that low AFR predicted a worse outcome for OS (HR 1.76, 95% CI 1.51–2.06, <i>p</i> < 0.001) and PFS (HR 1.50, 95% CI 1.29–1.74, <i>p</i> < 0.001), and high FA score was associated with worse OS (HR 2.61, 95% CI 1.75–3.90, <i>p</i> < 0.001) and PFS (HR 2.38, 95% CI 1.60–3.55, <i>p</i> < 0.001).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This meta-analysis demonstrated that a low AFR and a high FA score were associated with an increased risk of mortality and disease progression in LC, suggesting their potential as prognostic biomarkers.</p>\n </section>\n </div>","PeriodicalId":8158,"journal":{"name":"ANZ Journal of Surgery","volume":"95 7-8","pages":"1412-1420"},"PeriodicalIF":1.6000,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ANZ Journal of Surgery","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ans.70253","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

We aim to comprehensively assess the prognostic performance of AFR and FA scores in patients with lung cancer (LC).

Methods

We conducted a comprehensive search of PubMed, Web of Science, and CNKI databases to identify relevant studies. The primary endpoints assessed were overall survival (OS) and progression-free survival (PFS). Integrated hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated through pooling analysis.

Results

A total of 3145 participants from 10 studies were included in the analysis. In LC patients, the pooled results showed that low AFR predicted a worse outcome for OS (HR 1.76, 95% CI 1.51–2.06, p < 0.001) and PFS (HR 1.50, 95% CI 1.29–1.74, p < 0.001), and high FA score was associated with worse OS (HR 2.61, 95% CI 1.75–3.90, p < 0.001) and PFS (HR 2.38, 95% CI 1.60–3.55, p < 0.001).

Conclusion

This meta-analysis demonstrated that a low AFR and a high FA score were associated with an increased risk of mortality and disease progression in LC, suggesting their potential as prognostic biomarkers.

Abstract Image

查看原文本刊更多论文

白蛋白与纤维蛋白原比值、纤维蛋白原与白蛋白评分在肺癌患者中的预后价值：一项荟萃分析。

背景：我们旨在全面评估肺癌（LC）患者AFR和FA评分的预后表现。方法：综合检索PubMed、Web of Science和CNKI数据库，确定相关研究。评估的主要终点是总生存期（OS）和无进展生存期（PFS）。通过池化分析计算综合风险比（hr）和95%置信区间（ci）。结果：来自10项研究的3145名参与者被纳入分析。在LC患者中，汇总结果显示，低AFR预测较差的OS预后（HR 1.76, 95% CI 1.51-2.06, p）。结论：该荟萃分析表明，低AFR和高FA评分与LC患者死亡和疾病进展风险增加相关，提示它们具有作为预后生物标志物的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ANZ Journal of Surgery 医学-外科

CiteScore

2.50

自引率

11.80%

发文量

720

审稿时长

2 months

期刊介绍： ANZ Journal of Surgery is published by Wiley on behalf of the Royal Australasian College of Surgeons to provide a medium for the publication of peer-reviewed original contributions related to clinical practice and/or research in all fields of surgery and related disciplines. It also provides a programme of continuing education for surgeons. All articles are peer-reviewed by at least two researchers expert in the field of the submitted paper.